BioVie to Present Protocol Design for Upc... - Cure Parkinson's
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease
![Farooqji profile image](https://images.hu-production.be/avatars/d2bcede6695608a9d172b4c00f6b376c_small@2x_100x100.jpg)
Written by
![Farooqji profile image](https://images.hu-production.be/avatars/d2bcede6695608a9d172b4c00f6b376c_small@2x_100x100.jpg)
Farooqji
To view profiles and participate in discussions please or .
1 Reply
•
prior to taking any medication - it seems like the first thing neurologists suggest is taking medication so how will they find enough participants
Not what you're looking for?
You may also like...
First Patient Dosed in Phase 3 Trial of Buntanetap for Early Parkinson's
speed of movement and coordination....
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
samples accounting for placebo....
Dr. Tom Foltynie of Cure Parkinson’s Addresses Bydureon (Exanatide) Phase III Trial.
significance of the March 3, 2021 publication date.
https://youtu.be/FwSxbrQnBkc
Potential disease-modifying therapy enters Phase 2
disease.\\"
------------------------------------
https://youtu.be/aQfvVEXgmfc
Patients with Parkinson’s disease (PD) report a strong craving for sweets
Consequences of a Still Unclear Craving 2022...